酮体:SGLT2抑制剂的雙刃剑?
本文探讨SGLT2抑制剂通过轻度升高全身酮体水平可能介导其心肾获益,但酮症酸中毒是该类药物的罕见并发症,有时血糖正常或接近正常,在超说明书使用此类药物的1型糖尿病患者中更常见。
要点
- SGLT2抑制剂可轻度升高全身酮体水平
- 酮体可能介导SGLT2抑制剂的心肾获益
- 酮症酸中毒是SGLT2抑制剂的罕见并发症,有时血糖正常或接近正常
核心结论
- SGLT2抑制剂更严重不良反应之一的基础可能至少部分解释其部分获益,即该类药物潜在的「双刃剑」效应。
研究设计与样本
- 本文为综述,探讨SGLT2抑制剂与酮体相关的获益与风险。
主要发现
- SGLT2抑制剂通过靶向肾脏葡萄糖转运、阻止其重吸收而诱导糖尿,从而降低高血糖。
- SGLT2抑制剂除改善HbA1c、降低体重和血压外,还被证实改善心血管和肾脏结局,该效应在很大程度上独立于其对血糖水平的作用。
- SGLT2抑制剂治疗可轻度升高全身酮体水平。
- 酮体作为辅助燃料源在某些组织中替代葡萄糖,并可能具有内在的抗氧化和抗炎作用。
- 酮症酸中毒是SGLT2抑制的罕见并发症,有时血糖正常或接近正常,尽管在接受此类药物(主要为超说明书使用)治疗的1型糖尿病患者中更常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used by individuals with type 2 diabetes that reduce hyperglycaemia by targeting glucose transport in the kidney, preventing its reabsorption, thereby inducing glucosuria. Besides improving HbA1c and reducing body weight and blood pressure, the SGLT2 inhibitors have also been demonstrated to improve cardiovascular and kidney outcomes, an effect largely independent of their effect on blood glucose levels. Indeed, the mechanisms underlying these benefits remain elusive. Treatment with SGLT2 inhibitors has been found to modestly increase systemic ketone levels. Ketone bodies are an ancillary fuel source substituting for glucose in some tissues and may also possess intrinsic anti-oxidative and anti-inflammatory effects. Some have proposed that ketones may in fact mediate the cardio-renal benefits of this drug category. However, a rare complication of SGLT2 inhibition is ketoacidosis, sometimes with normal or near-normal blood glucose concentrations, albeit occurring more frequently in patients with type 1 diabetes who are treated (predominately off-label) with one of these agents. We herein explore the notion that an underpinning of one of the more serious adverse effects of SGLT2 inhibitors may, in fact, explain, at least in part, some of their benefits-a potential 'double-edged sword' of this novel drug category.
引用
- Lupsa BC, Kibbey RG, Inzucchi SE, et al. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia. 2022. PMID: 36255460. doi:10.1007/s00125-022-05815-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。